Genmab teams up with BioNTech in immuno-oncology development and commercialisation agreement

Published: 19-May-2015
Research & Development

Makes an upfront payment of US$10m to BioNTech


Genmab of Denmark has entered into a technology agreement with German biotechnology company BioNTech to jointly research, develop and commercialise multiple bispecific antibodies for cancer immunotherapy.

The agreement will use technologies from both companies including BioNTech’s immunomodulatory antibodies and Genmab’s DuoBody technology platform.

Genmab will pay an upfront fee of US$10m to BioNTech and additional potential near-term payments of up to $5m if certain BioNTech assets are developed further.

  • Companies:
  • Genmab
  • BioNTech AG
See more

You may also like

Research & Development

Genmab finalises ProfoundBio acquisition

Read more
The $1.8bn acquisition allows Genmab exclusive access to ProfoundBio's clinical stage ADC Rina-S, as well as its ADC technology platforms

Trending Articles

  1. Syncona launches early-stage drug development company, Slingshot Therapeutics The novel early-stage pharmaceutical company aims to collaborate with academic institutions to bring their findings to the clinic, with their first programme centring around inflammatory disease
  2. Medac and chiron develop organ-on chip tech for animal free drug testing The companies aim to develop an animal-free pharmaceutical testing method that utilises organ-on chip technology, and will be used in rheumatoid arthritis drug testing
  3. IMed Consultancy enabling innovation in the mental healthcare sector with Limbic Limbic is a London-based start-up that is using world-leading, clinically validated Artificial Intelligence and beautiful product design to make psychological therapy accessible for everyone, everywhere
  4. How iPSCs can bridge the translational gap in neuroscience Affecting more than one in three people, neurological disorders have a vast impact on global health while exacting a tremendous cost, reports Dr Max Mirza, Vice President of Neuroscience Drug Discovery at Sygnature Discovery
  5. RCPE and InSilicoTrials to digitalise and accelerate the development of pharmaceutical manufacturing processes RCPE and InSilicoTrials have agreed to an exclusive partnership to commercialise the XPS simulation software. Specifically developed for pharmaceutical applications, XPS allows companies to assess their process configurations in unprecedented detail and explore the decision space without time- and labour-intensive experiments

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Research & Development

Genmab finalises ProfoundBio acquisition

The $1.8bn acquisition allows Genmab exclusive access to ProfoundBio's clinical stage ADC Rina-S, as well as its ADC technology platforms
Regulatory

ImaginAb announces supply agreement with Genmab

The non-exclusive worldwide agreement provides Genmab a license to use the company’s CD8 ImmunoPET imaging technology
Research & Development

Genmab and Synaffix enter into ADC license agreement

Genmab will be responsible for the research, development, manufacturing and commercialisation of any resulting ADC therapies
Ingredients

Pfizer and BioNTech announce early positive vaccine update

Collaboration has announced results from German Phase 1/2 COVID-19 vaccine study, including first T-Cell response data
Research & Development

BioNTech and Pfizer dose first cohort of Phase I/II COVID-19 vaccine trial

The trial is the first clinical trial of a COVID-19 vaccine candidate in Germany and there are plans to initiate trials in the US upon regulatory approval
Research & Development

Personalised cancer treatment 2.0: new combination strategy developed

Tumours often comprise groups of cancer cells that show differential drug sensitivities, one of the reasons that initially effective treatments usually do not lead to long-term benefit in patients
Ingredients

Tisotumab Vedotin co-developed by Genmab and Seattle Genetics

Genmab and Seattle Genetics announced Seattle Genetics has exercised its option to co-develop tisotumab vedotin
Subscribe now